Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.

Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed. On CNBC’s Closing Bell Overtime, Fairlead Strategies founder Katie Stockton argued that financials, industrials, and biotech look ready to take over leadership as semiconductor and memory names show their first signs of fatigue. For investors, the cleanest way to express that view is through three sector ETFs.

Stockton’s case rests on technical breakouts driven by chart structure rather than fundamentals. That means these are intermediate- and short-term trade setups, and they carry the risk that breakouts fail to confirm. Stockton herself flagged that the XLF and XLI breakouts are still pending confirmation, and she urged patience rather than chasing.

Financials: XLF Clears a Key Line

The Financial Select Sector SPDR Fund (NYSEARCA:XLF) is Stockton’s marquee call. She pointed to XLF breaking above its 200-day moving average as “a bullish intermediate-term indication,” with leadership coming largely from banks and regional banks. Her advice is unusual for a breakout call: wait for the next pullback rather than chase strength here.

The price action supports the “just breaking out” framing. XLF closed at $53.57, up 1.81% on the week and 4.83% on the month, yet still down 1.69% year to date. Over a full year, the fund has returned 8.31%. That coiled, flat-YTD profile is exactly the setup technicians prize: a long base, then a thrust above the trend line.

Industrials: XLI Punches Through Resistance

The Industrial Select Sector SPDR Fund (NYSEARCA:XLI) is Stockton’s breadth tell. She highlighted XLI clearing resistance from the February-March highs, calling the move a “testament to market breadth as having expanded a little bit from technology.”

Industrials are already showing the strength a breakout implies. XLI sits at $180.91, up 3.29% on the week, 7.21% on the month, 16.95% year to date, and 28.91% over the past year. Aerospace and defense, machinery, transports, and building products carry the weight here, sectors that benefit directly when capital rotates out of crowded mega-cap tech and into cyclicals.

Biotech: XBI Breaks Out of Consolidation

The SPDR S&P Biotech ETF (NYSEARCA:XBI) is Stockton’s short-term trade. She flagged short-term breakouts from consolidation patterns and described biotech as a “standalone within healthcare” acting well outside the main leadership groups.

XBI is equal-weighted, which spreads risk across small- and mid-cap biotech rather than concentrating it. Per the official State Street fact sheet, the net expense ratio is just 0.35%, and no single position exceeds 2%. Top holdings include Apellis Pharmaceuticals (1.83%), Alkermes (1.45%), and Madrigal Pharmaceuticals (1.38%).

Performance backs the breakout: XBI trades at $140.72, up 6.01% on the week, 10.99% on the month, 15.41% year to date, and a striking 70.85% over the past year. Stockton’s call frames this as an opportunistic short-term trade with a limited duration window.

The Caution Underneath the Call

Stockton is rotating within the bull case on tech rather than walking away from it. She noted momentum cracks already visible in NVIDIA and Broadcom, warning that if the weakness spreads to memory stocks, the broader semiconductor complex could face headwinds. She also pointed out that Intel surged to a new high above $133, but its 20-day moving average wavered with the recent pullback, a sign that even the year’s hottest single-stock turnaround is showing slowing momentum.

The takeaway for investors: leadership is broadening, and three sector ETFs offer clean technical exposure to that rotation. Stockton’s own discipline (wait for pullbacks in XLF, treat XBI as short-term, demand confirmation on the breakouts) is the framework worth borrowing alongside the trade ideas themselves.